SCHEDULE 13G/A: Wellington Management Group Discloses Minor Stake in Syndax Pharmaceuticals

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 0.04% in Syndax Pharmaceuticals, Inc.'s common stock.

Summary

• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP jointly filed an Amendment No. 3 to Schedule 13G.
• The filing reports their beneficial ownership in Syndax Pharmaceuticals, Inc. common stock.
• As of February 28, 2025, the aggregate amount beneficially owned by the reporting persons is 35,681 shares.
• This represents 0.04% of the class of Syndax Pharmaceuticals, Inc. common stock.
• The reporting persons hold shared voting power over 32,075 shares and shared dispositive power over 35,681 shares, with no sole voting or dispositive power.
• The shares are held on behalf of clients of various Wellington Investment Advisers, with no single client known to own more than 5% of the class.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing a passive ownership stake. It contains no positive or negative news about the company's operations or financial performance, thus maintaining a neutral sentiment.

Positives

• The filing indicates a routine disclosure by a major investment firm, Wellington Management Group, holding shares in Syndax Pharmaceuticals, Inc.
• The ownership is for investment purposes in the ordinary course of business, not for control.

Negatives

• The reported beneficial ownership of 0.04% is a very small stake, indicating minimal direct influence or significant investment conviction from this specific filing.

Risks

• No specific risks related to Syndax Pharmaceuticals, Inc. are detailed in this ownership disclosure filing. The filing itself is a routine regulatory update.

Future Outlook

NA

Industry Context

This filing is a standard disclosure by an institutional investor, Wellington Management Group, regarding its passive ownership stake in a pharmaceutical company, Syndax Pharmaceuticals. It reflects a routine investment activity within the asset management industry, where large firms manage diversified portfolios for their clients. It does not provide specific insights into the broader pharmaceutical industry trends or competitive landscape.

Comparison to Industry Standards

• This is a standard Schedule 13G filing, indicating passive beneficial ownership below the 5% threshold.
• Large institutional investors like Wellington Management Group routinely file such disclosures for their holdings across various industries, including pharmaceuticals.
• The 0.04% stake is a very minor position, typical for a diversified fund's holding in a large portfolio, and does not suggest a strategic or concentrated investment compared to activist investors who might acquire larger stakes (e.g., 5% or more, triggering a Schedule 13D filing) to influence corporate governance or strategy.
• No specific comparable companies, projects, or results are mentioned in this filing.

Stakeholder Impact

• Shareholders: Provides transparency regarding a minor institutional ownership stake, confirming a passive investment approach by Wellington Management Group.
• Employees, Customers, Suppliers, Creditors: No direct impact as this filing is solely about beneficial ownership and does not relate to operational or financial performance.

Key Dates

Keywords

Syndax Pharmaceuticals, Wellington Management Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Pharmaceuticals